News | October 02, 2008

Prehospital Recognition, Fast Track Treatment Lowers Mortality in STEMI Patients

October 3, 2008 - A Swedish study shows patients transported with ambulance due to ST-elevation myocardial infarction (STEMI), there was a significant association between early recognition and treatment followed by fast tracking to a coronary care unit (CCU) and long-term survival.

The study appears in the October issue of the International Journal of Cardiology (Volume 129, Issue 3, Pages 325-332). It compared short-term outcomes of STEMI patients who were sent to the emergency department as compared to fast-tracked patients sent directly to a CCU. It found a higher rate of and a more rapid revascularization in patients sent to CCUs.

To describe the short-and long-term outcome among patients with an, assessed and treated by the emergency medical services (EMS) in relation to whether they were fast tracked to (CCU) or admitted via the emergency department (ED).

Patients admitted to the CCU at Sahlgrenska University Hospital in Göteborg, Sweden with ST elevations on admission ECG were analyzed with respect to whether EMS fast tracked them to the CCU or the adjacent coronary angiography laboratory (261 patients) or admitted via the ED (235 patients). Researchers said the two groups were similar with regard to age and previous history, those who were fast tracked to CCU were more frequently than the ED patients diagnosed and treated as STEMI already prior to hospital admission. Reperfusion therapy was more commonly applied in the CCU group compared with the ED group (90 percent vs. 67 percent). The delay times (median) were shorter in the direct CCU group than in the ED group, with a difference of 10 minutes from the onset of symptoms to arrival in hospital and 25 minutes from hospital arrival to the start of reperfusion treatment (primary PCI or in-hospital fibrinolysis).
Patients in the direct CCU group had lower 30-day mortality (7.3 percent vs. 15.3 percent), as well as late mortality (>30 days to five years) (11.6 percent vs. 20.6 percent).
The research was conducted by the Prehospital Research Centre, University Collage of Borås, Borås, Sweden, the Institution of Internal Medicine, department of metabolism and cardiovascular research, Sahlgrenska University Hospital, Göteborg, Sweden, the department of clinical physiology, Sahlgrenska University Hospital, Göteborg, Karolinska Institution, Stockholm, Sweden, and Astra Zeneca R&D, Mölndal, Sweden.

For more information: www.internationaljournalofcardiology.com

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init